Edition:
United States

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

3.48USD
20 Feb 2018
Change (% chg)

$0.28 (+8.75%)
Prev Close
$3.20
Open
$3.17
Day's High
$3.48
Day's Low
$3.14
Volume
8,618
Avg. Vol
11,187
52-wk High
$11.20
52-wk Low
$3.00

Chart for

About

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.... (more)
No analyst recommendations are available for .

Overall

Beta: 1.62
Market Cap(Mil.): $7.63
Shares Outstanding(Mil.): 2.37
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 180.40 17.28
EPS (TTM): -- -- --
ROI: -- -0.52 35.61
ROE: -- -3.30 17.17

BRIEF-RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

* RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH

Jan 16 2018

BRIEF-RXi Pharmaceuticals Announces Reverse Stock Split

* RXI PHARMACEUTICALS CORP - ANNOUNCED A REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-10

Jan 05 2018

BRIEF-RXi Pharma Announces Meets Secondary Objective With RXI-109 For Dermal Scarring

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH RXI-109 FOR DERMAL SCARRING

Dec 18 2017

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS

Dec 11 2017

BRIEF-RXi Pharma and Gustave Roussy have entered into a collaborative research agreement​

* RXi Pharmaceuticals Corp - ‍co, Gustave Roussy announced that they have entered into a collaborative research agreement​

Nov 13 2017

BRIEF-RXi Pharmaceuticals reports Q3 2017 financial results and recent corporate highlights

* Reports third quarter 2017 financial results and recent corporate highlights

Nov 08 2017

Earnings vs. Estimates